Prof Paul Kalra (Portsmouth Hospitals NHS Trust, UK) joins us onsite to discuss the IRONMAN trial (NCT02642562).
The IRONMAN trial aimed to study the effectiveness of intravenous iron in patients with heart failure and iron deficiency when compared to standard care. It showed that administration of IV FDI led to lower rates of recurrent heart failure hospitalisations and cardiovascular death. In this interview, Prof Kalra provides insight into some substudies of the trial, providing updates on rates of anaemia, iron deficiency and the quality-of-life of the patients enrolled in the trial. Results show increasing data on the safety profile of intravenous iron, and improved quality-of-life in patients.
Interview Questions:
1. Please briefly outline the IRONMAN Trial.
2. What were the substudies you presented at HFA 23?
3. What are the main findings?
4. What are your take-home messages for clinicians?
5. What further study is required?
Recorded on-site at HFA 23, in Prague.
Visit Radcliffe Cardiology: [ Ссылка ]
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: [ Ссылка ]
Follow us on Twitter: [ Ссылка ]
